Global adverse.events@ipsen.com Algérie pharmacovigilance.algeria@ipsen.com Australie pharmacovigilance.australia@ipsen.com Autriche pharmacovigilance.germany@ipsen.com Belgique pharmacovigilance.belgium@ipsen.com Brésil pharmacovigilance.brasil@ipsen.com Canada pharmacovigilance.canada@ipsen.com Chine pharmacovigilance.china@ipsen.com Hong Kong – PRC pharmacovigilance.hongkong@ipsen.com Colombie pharmacovigilance.colombia@ipsen.com République Tchèque pharmacovigilance.czech@ipsen.com Danemark pharmacovigilance.nordic@ipsen.com Finlande pharmacovigilance.nordic@ipsen.com France pharmacovigilance.france@ipsen.com Allemagne pharmacovigilance.germany@ipsen.com Grèce pharmacovigilance.greece@ipsen.com Hongrie pharmacovigilance.hungary@ipsen.com Irlande pharmacovigilance.uk-ie@ipsen.com Italie pharmacovigilance.italy@ipsen.com Japon pv.japan@ipsen.com Kazakhstan pharmacovigilance.kazakhstan@ipsen.com Corée du Sud pharmacovigilance.korea@ipsen.com Lettonie pharmacovigilance.baltic@ipsen.com Lituanie pharmacovigilance.baltic@ipsen.com Luxembourg pharmacovigilance.belgium@ipsen.com Mexique pharmacovigilance.mexico@ipsen.com Pays-Bas pharmacovigilance.netherlands@ipsen.com Norvège pharmacovigilance.nordic@ipsen.com Pologne pharmacovigilance.poland@ipsen.com Portugal pharmacovigilance.portugal@ipsen.com Roumanie pharmacovigilance.romania@ipsen.com Russie pharmacovigilance.russia@ipsen.com Singapour pharmacovigilance.sg@ipsen.com Slovaquie pharmacovigilance.slovakia@ipsen.com Espagne pharmacovigilance.spain@ipsen.com Suède pharmacovigilance.nordic@ipsen.com Suisse pharmacovigilance.germany@ipsen.com Taiwan pharmacovigilance.taiwan@ipsen.com Tunisie pharmacovigilance.tunisie@ipsen.com Ukraine pharmacovigilance.ukraine@ipsen.com Emirats Arabes Unis pharmacovigilance.ksa@ipsen.com Royaume-Uni pharmacovigilance.uk-ie@ipsen.com Etats-Unis pharmacovigilance.usa@ipsen.com Vietnam pharmacovigilance.vietnam@ipsen.com